MDGL Madrigal Pharmaceuticals, Inc.
USHealthcareAs of 2026-07-10 16:00
Why MDGL matters now
Madrigal Pharmaceuticals, Inc. (MDGL) is a US stock in Healthcare. The latest InvestLog snapshot shows $536.70 with -4.16% on the session and $12.37B in market capitalization; recent performance reads 1-month -1.19% and YTD -13.15%.
The latest financial table shown here is Q1 2026, with revenue of $311.3M, net income of $-94.4M, and EPS of $-3.25. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -2.3%.
The latest indexable market news headline is "3 Under-the-Radar Stocks to Buy and Hold" from The Motley Fool.
Additional event context on this page matters because analyst consensus is Buy with a median target of $579.00; recent insider activity includes BAKER BROS. ADVISORS LP filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
27.02
P/S
10.30
EV/EBITDA
-41.89
DCF Value
$2,867.98
FCF Yield
-2.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
93.1%
Operating Margin
-27.7%
Net Margin
-27.3%
ROE
-50.2%
ROA
-25.2%
ROIC
-35.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $311.3M | $-94.4M | $-3.25 |
| Q4 2025 | $321.1M | $-58.6M | $-2.57 |
| FY 2025 | $958.4M | $-288.3M | $-12.85 |
| Q3 2025 | $287.3M | $-114.2M | $-5.08 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$656.00
Target (Median)
$579.00
Target Range
$542.00 - $964.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
-1.06
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.